The 17th International Conference on Brain Tumor Research and Therapy■PROGRAM
June 10 (1 st day)
08:30

OPENING REMARKS●Basic Science I. EGFR
Chairpersons:C. David James (USA), Motoo Nagane (Japan)

08:45

BS 109:00

BS 2

09:15

BS 3

09:30

BS 4THE ROLE OF EGF RECEPTOR HETEROGENEITY IN DRIVING GLIOMADEVELOPMENTFrank Furnari (USA)ABERRANT EGFR SIGNALING IN GLIOMA
Oliver Boegler (USA)THE ROLE OF EGFR* SIGNALING PATHWAY FOR TUMOR MAINTENANCE AND
ALTERNATIVE PATHWAYS IN GLIOBLASTOMA WHICH ENHANCE TUMORGROWTHAkitake Mukasa (Japan)
EGF RECEPTOR TYROSINE KINASE MEDIATES A NOVEL PATHWAY OF DRUGRESISTANCE IN MALIGNANT GLIOMAS VIA TYROSINE PHOSPHORYLATIONAND FUNCTIONAL ACTIVATION OF GLUTATHIONE S- TRANSFERASE P1Tatsunori Okamura (USA)●Basic Science II. Genetic and Expression Profile. Markers.
Chairpersons:Rolf Bjerkvig (Norway), Chifumi Kitanaka (Japan)

09:55

BS 5

10:10

BS 6

10:20

BS 7

MULTIGENE PREDICTOR OF OUTCOME IN NEWLY DIAGNOSEDGLIOBLASTOMA
Kenneth D. Aldape (USA)
USING GENE EXPRESSION PROFILING TO IDENTIFY A PROGNOSTIC
MOLECULAR SPECTRUM IN GLIOMASMitsuaki Shirahata (Japan)SPHINGOSINE-1-PHOSPHATE1 RECEPTOR REGULATES GLIOMA CELLPROLIFERATION AND CORRELATES WITH SURVIVAL OF PATIENTS WITHGLIOBLASTOMA
Yuya Yoshida (Japan)

10:30

Coffee Break●Basic Science III. Invasion, Immunoresistance
Chairpersons:Frank Furnari (USA), Mitsutoshi Nakada (Japan)

11:00

BS 8

11:03

BS 9

11:06

BS 10

11:10

BS 11

11:20

BS 12

11:30

BS 13

* 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN DOWN- REGULATESHYALURONIC ACID-INDUCED GLIOMA INVASION BY BLOCKING MMP-9SECRETION
Seung H Lee (Korea)* INHIBITIION OF GLIOMA INVASION BY SILENCING SPARC WITH SIRNATakanori Ohnishi (Japan)* THE ROLE OF CHEMOKINE, SDF-1 AND CXCR4 IN GLIOMA ANGIOGENESIS ANDINVASIVENESS: INTERACTION BETWEEN GLIOMA AND GLIOMA DERIVED
ENDOTHELIAL CELLS
Shingo Takano (Japan)
THE GUANINE NUCLEOTIDE EXCHANGE FACTORS TRIO, ECT2, AND VAV3MEDIATE THE INVASIVE BEHAVIOR OF GLIOBLASTOMAJames Rutka (Canada)
ELMO1 AND DOCK180, A BIPARTITE RAC1 GUANINE NUCLEOTIDEEXCHANGE FACTOR, PROMOTE HUMAN GLIOMA CELL INVASIONShiyuan Cheng (USA)A NOVEL SWITCH THAT LINKS PTEN TO THE CONTROL OF UBIQUITINATION,TRAIL SENSITIVITY, AND IMMUNORESISTANCE IN HUMAN GBM XENOGRAFTCELLSRussell O. Pieper (USA)*Posters are also displayed in the Poster Viewing Room.

– 12 –June 9-12, 2008 Hakodate, Japan●Lunchtime Seminar: Temozolomide plus Interferon-beta for newly diagnosed
GBM: INTEGRA study(Sponsor: Toray Industries Co., Ltd.)
Chairperson:

Soichiro Shibui (Japan)

12:00

A JAPANESE MULTICENTER CLINICAL TRIAL OF INTERFERON-B ANDTEMOZOLOMIDE COMBINATION THERAPY FOR HIGH-GRADE GLIOMAS:FROM BENCH TO BEDSIDEAtsushi Natsume (Japan), Toshihiko Wakabayashi (Japan)

LS●New Therapeutic Approaches I
Chairpersons:Mitchel S. Berger (USA), Keisuke Ueki (Japan)

13:00

New 1

13:10

New 2

13:20

New 4

13:30

New 5

13:40

New 6

13:50

New 7

14:05

New 8

14:20

Stem 8ENHANCING GLIOBLASTOMA CYTOTOXIC THERAPY THROUGH SMALL
MOLECULE INHIBITION OF P53
C. David James (USA)CYCLIN-DEPENDENT KINASE INHIBITOR FLAVOPIRIDOL ENHANCESCYTOTOXIC ACTION OF DNA-DAMAGING AGENTS ON HUMAN GLIOMA
CELLS
Yuichi Hirose (Japan)
BORON NEUTRON CAPTURE THERAPY FOR NEWLY DIAGNOSEDGLIOBLASTOMAShin-Ichi Miyatake (Japan)
MODULAR RECOMBINANT TRANSPORTERS: A FLEXIBLE PLATFORM FOR
BRAIN TUMOR TARGETED RADIONUCLIDE THERAPY
Michael R. Zalutsky (USA)
NANO-PARTICLE MICELLE AS A DRUG DELIVERY SYSTEM FOR BRAIN TUMORTHERAPY
Yasushi Ino (Japan)
MR PARAMETERS AS NON-INVASIVE BIOMARKERS FOR PREDICTINGSURVIVAL IN NEWLY DIAGNOSED PATIENTS WITH GLIOBLASTOMA
MULTIFORMESusan M. Chang (USA)TREATMENT OF CNS RADIATION NECROSIS WITH BEVACIZUMAB, AN ANTIVEGF ANTIBODYVictor A. Levin (USA)TUMOR-DERIVED MESENCHYMAL STEM CELLS IN HUMAN GLIOMASFrederick F. Lang (USA)

14:30

Coffee Break●Evening Symposium: Clinical Trials and Related Information(Sponsor: Schering-Plough K.K.)
Chairpersons:

Jan Buckner (USA), Tomokazu Aoki (Japan)

15:00

CT 10

15:12

CT 11

15:32

CT 12

15:44

CT 13

A CLINICAL TRIAL FOR MALIGNANT GLOMAS BY JCOG-BRAIN TUMORSTUUDY GROUP (JCOG 0305)
Soichiro Shibui (Japan)
PROGNOSTIC VARIABLES IN RECURRENT HIGH-GRADE GLIOMA CLINICAL
TRIALS: AN NCCTG AND NABTC JOINT ANALYSISJan Buckner (USA)A PHASE I/IB STUDY OF TEMOZOLOMIDE (TMZ) AND THEFARNESYLTRANSFERASE INHIBITOR, LONAFARNIB (SARAZARTM, SCH66336)
IN RECURRENT, TMZ REFRACTORY GLIOBLASTOMA (GBM)
Mark R. Gilbert (USA)Metronomic temozolomide treatment in patients with recurrent temozolomiderefractory glioblastoma
Jong-Hyun Kim (Korea)– 13 –

The 17th International Conference on Brain Tumor Research and Therapy

15:56

CT 14

16:08

CT 15

17:30-19:30

AN INTERGROUP PHASE III STUDY OF RADIATION THERAPY WITH OR
WITHOUT TEMOZOLOMIDE FOR SYMPTOMATIC OR PROGRESSIVE LOWGRADE GLIOMASDavid Schiff (USA)THE EORTC BRAIN TUMOR GROUP: CURRENT DEVELOPMENTS
Martin J. van den Bent (Netherlands)
Garden Party●Poster Presentation
Chairperson:

Kazuhiko Mishima (Japan)

20:30

CT 1

20:33

CT 2

20:36

CT 3

20:39

CT 4

20:42

CT 5

20:45

CT 6

20:48

CT 7

20:51

CT 9

20:54

BS 14

20:57

BS 15

21:00

BS 16

21:03

BS 17

21:06

BS 18

21:09

BS 19

21:12

BS 20

TREATMENT RESULT OF ANAPLASTIC OLIGODENDROGLIOMAS: PERSONALEXPERIENCE
Young-Cho Koh (Korea)
BRAIN ATROPHY AND COGNITIVE FUNCTION FOLLOWING CHEMOTHERAPYTO OLIGODENDROGLIOMAKeisuke Ueki (Japan)
AN ULTRASTRUCTURAL, IMMUNOHISTOCHEMICAL AND MORPHOMETRICSTUDY OF OLIGODENDROGLIOMAS WITH RESPECT TO CHROMOSOME 1PDELETIONTakashi Komori (Japan)
GENETIC PROFILE IN 1P- AND 19Q- DELETED OLIGODENDROGLIOMA WITHSHORT RELAPSE-FREE SURVIVAL
Jun-ichi Adachi (Japan)
DIFFERENTIAL ASSOCIATION OF CHROMOSOME 19 SNP VARIANTS WITHOLIGODENDROGLIOMA: A CASE-CASE COMPARISON
Robert B. Jenkins (USA)
AGE, PREOPERATIVE KPS AND MGMT PROMOTOR HYPERMETHYLATIONDEFINE THE SURVIVAL OF THE PATIENTS WITH GLIOBLASTOMAYukihiko Sonoda (Japan)
MGMT PROMOTER METHYLATION STATUS IS A STRONG PREDICTIVEFACTOR FOR RESPONSE TO ACNU (NITROSOUREA) BASED RADITATIONTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMASYoshitaka Narita (Japan)
PHASE II STUDY OF LOW DOSE ICE (IFOSFAMIDE, CARBOPLATIN ANDETOPOSIDE) FOR RECURRENT GLIOBLASTOMATomokazu Aoki (Japan)
CENTROSOME AMPLIFICATION INDUCED BY SURVIVIN SUPPRESSIONENHANCES BOTH CHROMOSOME INSTABILITY AND RADIOSENSITIVITY INGLIOMA CELLS
Kaoru Kurisu (Japan)
THE WARBURG EFFECT AND TUMOR CELL SURVIVAL IN HUMAN GBMAbhijit Guha (Canada)
GENETIC AND HYPOXIC MECHANISMS OF TISSUE FACTOR EXPRESSION AND
THROMBOSIS IN GLIOBLASTOMA
Daniel J. Brat (USA)GATA4 EXPRESSION IN THE NORMAL CNS AND ITS FREQUENT LOSS IN
HUMAN GLIOMASAbhijit Guha (Canada)
THE EXPRESSION LEVEL OF S1P1 IS RELATED TO MIB-1 LABELING INDEX
WHICH PREDICTS SURVIVAL IN GLIOBLASTOMA
Mitsutoshi Nakada (Japan)
ENHANCED TUMOR GROWTH ELICITED BY L- TYPE AMINO ACID
TRANSPORTER 1 IN HUMAN MALIGNANT GLIOMA CELLS
Motoo Nagane (Japan)
THE RNA BINDING PROTEIN 76 CONTROLS GENE EXPRESSION IN GBM
Matthias Gromeier (USA)*Posters are also displayed in the Poster Viewing Room.

– 14 –June 9-12, 2008 Hakodate, Japan

21:15

BS 21

21:18

BS 22

21:21

BS 23

21:24

BS 24

21:27

BS 27

EXPRESSION AND FUNCTIONAL SIGNIFICANCE OF INHIBITORS OF
APOPTOSIS PROTEINS (IAPS)IN HUMAN GLIOMASAbhijit Guha (Canada)
DUAL BLOCKADE OF LIPID AND PROTEIN KINASES DRIVES APOPTOSIS IN
GLIOMAWilliam A. Weiss (USA)TARGETING THE TUMOR STROMA: A NOVEL THERAPEUTIC STRATEGYBASED ON SEPARATE ANALYSIS OF THE MALIGNANT AND STROMAL CELLCOMPARTMENTS IN BRAIN TUMORS.
Jian Wang (Norway)
THE ROLE OF GLIAL CELLS IN BRAIN METASTASES OF TUMOR CELLS
Mami Noda (Japan)
FORMATION AND FUNCTIONAL MAPPING OF THE INTERACTION DOMAIN OF
A PHYSICAL COMPLEX BETWEEN TGM2 AND GSTP1 THAT CONFERSCISPLATIN RESISTANCE IN MALIGNANT GLIOMA CELLSFrancis Ali-Osman (USA)

June 11 (2 nd day)●Cancer Stem Cell
Chairpersons:

Manfred Westphal (Germany), Hideyuki Saya (Japan)

Stem 1Cancelled

09:30

THE REAL AXIS OF EVIL: CANCER STEM CELLS IN TUMOR GROWTH,THERAPEUTIC RESISTANCE, AND ANGIOGENESIS
Anita B. Hjelmeland (USA)Stem 2 A HIERARCHY OF SELF-RENEWING TUMOR-INITIATING CELL TYPES INGLIOBLASTOMA
Heidi S. Phillips (USA)Stem 3 CHARACTERIZATION AND TRANSFORMATION POTENTIAL OF SYNTHETICASTROCYTES DIFFERENTIATED FROM MURINE EMBRYONIC STEM CELLSAbhijit Guha (Canada)
Stem 4 CLINICAL AND BIOLOGICAL IMPLICATION OF CD133 POSITIVE ANDNEGATIVE CELLS IN GLIOBLASTOMASDo-Hyun Nam (Korea)
Stem 5 CD133 POSITIVE CELLS ARE STABLY ENTRAPPED IN SHORT-TERM CELLLINES DERIVED FROM MALIGNANT ASTROCYTOMA AND CONTRIBUTE TOCHEMORESISTANCEJohn L. Darling (UK)
Discussion

09:45

Coffee Break

10:15

Stem 6

08:30

08:45

09:00

09:15

10:30

10:45

11:00

11:15

CANDIDATE STEM CELL POPULATION FOR USE IN CNS TUMOR THERAPY
Catherine T. Flores (UK)Stem 7 HUMAN ADULT BRAIN CONTAINS NEURO-GLIAL PROGENITOR CELLS WHICH
TARGET HUMAN GLIOMA XENOGRAFTS
Manfred Westphal (Germany)
Stem 9 CEREBELLAR STEM CELLS LACKING RB AND P53 ACT AS TUMOUR
INITIATING CELLS IN MEDULLOBLASTOMA PATHOGENESIS
Silvia Marino (UK)Stem 10 GLOBAL ANALYSES OF POLYCOMB MEDIATED TRANSCRPTIONALREPRESSION AND DNA METHYLATION TARGETS IN BRAIN TUMOR STEMCELLSAtsushi Natsume (Japan)
Discussion– 15 –The 17th International Conference on Brain Tumor Research and Therapy

12:00●Lunchtime Symposium: Primary CNS Lymphoma(Sponsor: Chugai Pharmaceutical Co., Ltd.)
Chairpersons:
12:15

12:30

12:45

13:00

13:03

Brian Patrick O’Neill (USA), Takanori Ohnishi (Japan)

PCNSL 1 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN JAPAN: CHANGES IN
CLINICAL FEATURES, TREATMENT AND PROGNOSIS DURING 1985-2004
Yuta Shibamoto (Japan)
PCNSL 2 RESPONSE AND SURVIVAL PATTERN IN PRIMARY CNS LYMPHOMA TREATEDBY HIGH DOSE METHOTREXATE MONOCHEMOTHERAPY: ROLE OF STAT6 AS
PROGNOSTIC DETERMINANTYong-Kil Hong (Korea)
PCNSL 3 IMMUNOCHEMOTHERAPY WITH RITUXIMAB IN CONJUNCTION WITHBLOOD-BRAIN BARRIER DISRUPTION AND AN ICE REGIMEN FOR RELAPSEDOR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS(PCNSL)
Kazuhiko Mishima (Japan)
PCNSL 4 *RACIAL/ETHNIC DIFFERENCES IN PRIMARY CENTRAL NERVOUS SYSTEMLYMPHOMA: A SEER-BASED ESTIMATE OF INCIDENCE AND SURVIVAL RATESAMONG UNITED STATES BLACKS, WHITES, ASIAN/PACIFIC ISLANDERS AND
AMERICAN INDIANS/ALASKAN NATIVES
Brian Patrick O’Neill (USA)PCNSL 5 *DEL (6)(Q22) AND BCL6 REARRANGEMENTS DETECTED BY INTERPHASEFLUORESCENCE IN-SITU HYBRIDIZATION (FISH) ARE UNFAVORABLECYTOGENETIC ABNORMALITIES IN IMMUNOCOMPETENT (IC) PATIENTSWITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
Brian Patrick O’Neill (USA)●Molecular Targeted Therapies(Sponsor: Daiichi Sankyo Co., Ltd.)
Chairpersons:Martin J. van den Bent (Netherlands), John L. Darling (UK)

13:45 ILBIOMARKERS FOR PREDICTIVE AND PROGNOSTIC FACTORS(Invited Lecture) Kazuto Nishio (Japan)
14:25 MTT 1PHASE II STUDY OF BEVACIZUMAB AND ERLOTINIB IN PATIENTS WITHRECURRENT GLIOBLASTOMA MULTIFORMEDavid A. Reardon (USA)14:45 MTT 3
FEASIBILITY/TOLERABILITY RESULTS FROM A PHASE I/II STUDY OFTEMSIROLIMUS (CCI-779) AND SORAFENIB IN RECURRENT GLIOBLASTOMA:NORTH CENTRAL CANCER TREATMENT GROUP (NCCTG) N0572
David Schiff (USA)
14:57 MTT 4PHASE I/II STUDY OF ERLOTINIB AND CCI-779 (TEMSIROLIMUS) FORPATIENTS WITH RECURRENT MALIGNANT GLIOMAS (NABTC 04-02)
Patrick Wen (USA)
15:30

Hakodate Sightseeing & Dinner

June 12 (3 rd day)●New Therapeutic Approaches IIChairpersons:
08:30

08:33

James Rutka (Canada), Tomoki Todo (Japan)

New 17 *A CLINICAL TRIAL OF CATIONIC LIPOSOMES CONTAINING INTERFERON-BETA
GENE FOR PATIENTS WITH MALIGNANT GLIOMAToshihiko Wakabayashi (Japan)
New 18 *ANTI-EGF-R ANTIBODIES IN A HIGHLY INVASIVE XENOTRANSPLANT MODELOF HUMAN GLIOMAManfred Westphal (Germany)*Posters are also displayed in the Poster Viewing Room.

– 16 –June 9-12, 2008 Hakodate, Japan

08:36

10:00

New 19 *DICER-REGULATED MICRO RNAS 222 AND 339 PROMOTE IMMUNE-ESCAPE
OF CANCER CELLS THROUGH DOWNREGULATION OF ICAM-1
Hideho Okada (USA)New 20 *THE DNA DEMETHYLATING AGENT 5- AZA-2-DEOXYCYTIDINE INDUCES THEEXPRESSION OF CANCER-TESTIS ANTIGENS IN HUMAN GLIOMAS:EPIGENETIC TARGET FOR TUMOR IMMUNOTHERAPY
Atsushi Natsume (Japan)
New 22 *WT1 (WILMS TUMOR GENE) PEPTIDE VACCINATION FOR PATIENTS WITHRECURRENT GLIOBLASTOMA
Shuichi Izumoto (Japan)
New 23 *IDENTIFICATION OF AN HLA- A24-RESTRICTED T-CELL EPITOPE DERIVED
FROM A GLIOMA-ASSOCIATED ANTIGEN, INTERLEUKIN 13 RECEPTOR ALPHA
2 CHAINToshihiko Wakabayashi (Japan)
New 9EXPERIMENTAL BRAIN TUMOR THERAPY USING ONCOLYTIC HSV-1 ARMED
WITH INTERLEUKIN 12Tomoki Todo (Japan)
New 11 DUAL-SPECIFIC IMMUNOTOXIN, D2C7 (scdsFv)-PE38KDEL, FOR BRAIN
TUMOR TREATMENTChien-Tsun Kuan (USA)New 12 RECOMBINANT ANTIBODY-BASED MOLECULAR THERAPEUTICS FOR BRAIN
TUMOR IMMUNOTHERAPYKenji Wakiya (Japan)
New 13 INDUCTION OF IMMUNOLOGIC AND CLINICAL RESPONSES WITH EGFRvIIITARGETED VACCINE (CDX-110) WITH CYCLES OF TEMOZOLOMIDE INPATIENTS WITH NEWLY DIAGNOSED EGFRvIII POSITIVE GBM
Gary E. Archer (USA)New 14 TYPE-1 DENDRITIC CELL (DC) VACCINES IN COMBINATION WITH POLY-ICLCIN PARTICIPANTS WITH RECURRENT MALIGNANT GLIOMA
Hideho Okada (USA)New 15 EFFICACY OF A RNA-PULSED DENDRITIC CELL VACCINES TARGETINGCYTOMEGALOVIRUS ANTIGENS IN NEWLY- DIAGNOSED GBMDuane A. Mitchel (USA)New 16 REAL TIME MONITORING FOR CONVECTION-ENHANCED DELIVERY OF
INTRATUMORAL CHEMOTHERAPY IS PREDICTIVE OF RESPONSE IN CANINESPONTANEOUS GLIOMAS
Krystof S. Bankiewicz (USA)Discussion

10:20

Coffee Break

08:39

08:42

08:45

08:48

08:58

09:08

09:18

09:28

09:38

09:48

●Pediatric Neuro-Oncology: CNSGCTChairpersons:

Jonathan Finlay (USA), Masao Matsutani (Japan)

11:00

PNO 1

11:20

PNO 2

11:40

PNO 3

11:50

PNO 4

11:53

PNO 6TREATMENT OF PRIMARY CNS GERMINOMATOUS GERM CELL TUMORS (GCT)WITH CHEMOTHERAPY PRIOR TO REDUCED DOSE VENTRICULAR FIELDIRRADIATION: THE CHILDRENS HOSPITAL LOS ANGELES EXPERIENCE 2003-2007
Jonathan Finlay (USA)LOW-DOSE RADIOTHERAPY AFTER INDUCTION CHEMOTHERAPY FORINTRACRANIAL GERMINOMASYutaka Sawamura (Japan)
TREATMENT RESULTS OF CONSECUTIVE 78 PATIENTS WITH INTRACRANIALGERMINOMA IN A SINGLE INSTITUTEToshihiro Kumabe (Japan)*CLINICAL EVALUATION OF PINEAL PARENCHYMAL TUMORS -HIROSHIMAUNIVERSITY HOSPITAL EXPERIENCESKazuhiko Sugiyama (Japan)*ENHANCED EXPRESSION OF DNA TOPOISOMERASE II GENES IN HUMANMEDULLOBLASTOMA AND ITS POSSIBLE ASSOCIATION WITH ETOPOSIDESENSITIVITY
Tadahisa Shono (Japan)*Posters are also displayed in the Poster Viewing Room.

– 17 –The 17th International Conference on Brain Tumor Research and Therapy

11:56

11:59
12:02
12:10

PNO 7

*IDENTIFICATION OF GENES AND PATHWAYS CRITICAL FOR TUMORINITIATION, MAINTENANCE, AND PROGRESSION IN A MURINE MODEL OF
LEPTOMENINGEAL METASTATIC MEDULLOBLASTOMA DRIVEN BY THESLEEPING BEAUTY TRANSPOSON
Michael D. Taylor (Canada)
PNO 8 *IDENTIFICATION OF NT-3/TRK-C REGULATED PROTEINS IN MEDULLOBLASTOMA
Irene Slavc (Austria)
PNO 10 *FACTORS AFFECTING OF MEDULLOBLASTOMAS IN CHILDREN
Tai-T Wong (Taiwan)
LUNCH●Medulloblastoma, PNET, AT/RT, Choroid plexus tumor
Chairpersons:Mark W. Kieran (USA), Takaaki Yanagisawa (Japan)

13:30

PNO 11

13:50

PNO 12

14:00

PNO 13

14:12

PNO 14

14:24

PNO 16

14:36

PNO 17

ADULTS WITH MEDULLOBLASTOMA: TIME FOR A CHANGE IN MANAGEMENTJonathan Finlay (USA)TREATMENT OF ORTHOTOPIC MEDULLOBLASTOMAS WITH METRONOMICTEMOZOLOMIDE AND 13-CIS-RETINOIC ACID
Anat Erdreich-Epstein (USA)MEDULLOBLASTOMA GROWTH ENHANCEMENT BY HGF/SF EXPRESSION INCEREBELLAR NEURAL PROGENITOR CELLS IS SUPPRESSED BY SYSTEMICANTIBODY TREATMENTDaniel W. Fults (USA)OTX2 is oncogenic and predicts decreased survival in medulloblastomas patients
Sridharan Gururangan (USA)RESULTS FROM A SINGLE-ARM, MULTI- INSTITUTIONAL PHASE II STUDY OF
MULTI-AGENT INTRATHECAL AND SYSTEMIC CHEMOTHERAPY WITH AGEAND RISK-ADAPTED RADIATION THERAPY FOR CHILDREN WITH NEWLYDIAGNOSED CNS ATYPICAL TERATOID/RHABDOID TUMORMark W. Kieran (USA)CPT-SIOP-2000 STUDY: A PLANET WIDE CHOROID PLEXUS TUMOR STUDY INTERIM REPORT OCTOBER 2007
Johannes E. A. Wolff (USA)

15:00

Coffee Break●Neurocognitive function and outcome
Chairperson:Ryo Nishikawa (Japan)

15:30

OUT 1

15:40

OUT 2

LATE EFFECTS FOLLOW-UP OF HEAD START II SURVIVORS
Stephen Sands (USA)NEUROPSYCHOLOGICAL OUTCOME OF SURVIVORS OF PEDIATRICMALIGNANT GLIOMA
Stephen Sands (USA)

16:00

CLOSING REMARKS

18:30-21:00
FAREWELL DINNER*Posters are also displayed in the Poster Viewing Room.

– 18 –